FDA approves Roche's breast cancer dual-targeted HER2 antibody combination: patobead monoyduminal and querta-supra

U.Sregulators have approved a fixed dose combination of Roche Phesgo (Pertuzumab, patozumab) and Herceptin (Trastuzumab, qural beadmonotagalyses) and hyaluronic acid asse for the treatment of early and metastatic HER2 positivebreast cancerThis is the first time Roche has been approved to administer two monoclonal antibodies with a single subcutaneous injectionThe treatment is administered in combination with intravenous (IV) injections of chemotherapyPhoto Source:Perjeta is a new anti-HER2 drug that acts as an anti-HER2 by inhibiting HER2 heterogeneous and homologous dipolymersPerjeta and Herceptin act on the same mechanism, both target binding to HER2 receptors, but the binding sites are differentCombining the two drugs, it can provide a more comprehensive blockade of the HER2 signaling pathway, thus preventing the growth and survival of cancer cellsthe initial dose of Phesgo takes about 8 minutes, followed by about 5 minutes per dose of maintenance, compared with 150 minutes for continuous infusionof of Perjeta and Herceptin with standard IV preparations and 60-150 minutes to maintain administrationRoche also said That Phesgo can be managed by health care workers at the treatment center or at the patient's homemanagePhesgo's approval is based on data from the FeDeriCa III study, which reached its primary endpoint and showed that the levels of Perjeta in the blood after subcutaneous injection showed non-inferiority compared to intravenous injectionsRoche stressed that phesgo combined chemotherapy was as safe as Perjeta's combined herceptin and chemotherapy, and no new safety signals were found